Efficacy and safety of recombinant human activated protein C for severe sepsis

Clicks: 461
ID: 111871
2001
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #33 of 183 articles by views in The New England journal of medicine

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 183 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Treatment with drotrecogin alfa activated significantly reduces mortality in patients with severe sepsis and may be associated with an increased risk of bleeding.
Reference Key
gr2001theefficacy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bernard GR;Vincent JL;Laterre PF;LaRosa SP;Dhainaut JF;Lopez-Rodriguez A;Steingrub JS;Garber GE;Helterbrand JD;Ely EW;Fisher CJ; ;;
Journal The New England journal of medicine
Year 2001
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/11236773
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't Prospective Studies Clinical Trial Randomized Controlled Trial Double-Blind Method Multicenter Study Survival Analysis risk fibrin fibrinogen degradation products / analysis interleukin-6 / blood pmid:11236773 doi:10.1056/nejm200103083441001 g r bernard j l vincent recombinant human protein c worldwide evaluation in severe sepsis (prowess) study group anti-inflammatory agents non-steroidal / adverse effects non-steroidal / pharmacology non-steroidal / therapeutic use* fibrinolytic agents / adverse effects fibrinolytic agents / pharmacology fibrinolytic agents / therapeutic use* hemorrhage / chemically induced infections / physiopathology protein c / adverse effects protein c / pharmacology protein c / therapeutic use* recombinant proteins / adverse effects recombinant proteins / pharmacology recombinant proteins / therapeutic use* systemic inflammatory response syndrome / blood systemic inflammatory response syndrome / drug therapy* systemic inflammatory response syndrome / mortality

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.